tanacetum boreale/inflammation

FIELD OF THE INVENTION This invention relates to the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium). BACKGROUND OF THE INVENTION Tanacetum parthenium, a plant commonly known as Feverfew, has been recognized since

FIELD OF THE INVENTION This invention relates to the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium). BACKGROUND OF THE INVENTION Tanacetum parthenium, a plant commonly known as Feverfew, has been recognized since

FIELD OF THE INVENTION The present invention relates to compositions that tend to exhibit anti-inflammatory properties, and more particularly, to compositions comprising combinations of anti-inflammatory agents, which compositions tend to exhibit unexpectedly high, synergistic anti-inflammatory

FIELD OF THE INVENTION The present invention relates to compositions that tend to exhibit anti-inflammatory properties, and more particularly, to compositions comprising combinations of anti-inflammatory agents, which compositions tend to exhibit unexpectedly high, synergistic anti-inflammatory

TECHNICAL FIELD The present invention relates to a composition having an anti-inflammatory activity, comprising extracts or fractions of Chrysanthemum boreale Makino. BACKGROUND ART Human skin undergoes changes with age due to various intrinsic and extrinsic factors. With respect to the intrinsic

FIELD OF THE INVENTION The present invention is directed to an edible composition for use as an anti-inflammatory agent for alleviation of arthritis and gout in mammals. The composition comprises a synergistic mixture of at least three herbs selected from a group of ten herbs identified

FIELD OF THE INVENTION This invention relates to the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium). BACKGROUND OF THE INVENTION Tanacetum parthenium, a plant commonly known as Feverfew, has been recognized since

FIELD OF THE INVENTION The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of .alpha.-unsaturated

FIELD OF THE INVENTION The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of .alpha.-unsaturated

BACKGROUND The present invention relates to inflammation within the body, and more particularly, to regulating inflammation to treat conditions and diseases associated therewith. Inflammation has been linked to a variety of conditions and diseases that affect the body. For example, inflammation

BACKGROUND OF THE INVENTION The present invention relates to inflammation within the body, and more particularly, to regulating inflammation to treat conditions and diseases associated therewith. Inflammation has been linked to a variety of conditions and diseases that affect the body. For example,

FIELD OF THE INVENTION The present invention relates to the field of topical applications of skin care compositions to the skin. The invention further relates to skin care compositions comprising blends of camellia and feverfew serum fractions and/or kelp and parsley serum fractions. The invention

1. FIELD OF THE INVENTION This invention relates to methods and compositions for mitigating irritation of mammalian skin. More particularly, it relates to compositions containing at least one alkanolamine in combination with feverfew, soy, or a mixture thereof for mitigating skin irritations such as

BACKGROUND Fibromyalgia is a disease characterized by widespread musculoskeletal pain and tenderness on palpation at so called tenderpoints. The disease is diagnosed according to criteria as defined by the American College of Rheumatology (ACR) [see Arthritis and Rheumatism, Vol. 33, No. 2, pages